| Detected | Trial | Change |
|---|---|---|
| 2026-06-12 | NCT07604272 Reversing InGuinal Hernia Trial: The Evaluation of Sex Hormones to Reverse Inguinal… |
Enrollment reduced: 75 -> 30 participants |
| 2026-06-12 | NCT07604272 Reversing InGuinal Hernia Trial: The Evaluation of Sex Hormones to Reverse Inguinal… |
Trial arms changed: 3 -> 2 |
| 2026-06-12 | NCT07391774 Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed… |
Trial sites expanded: 14 -> 18 locations |
| 2026-06-06 | NCT01953588 Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III… |
Primary endpoint(s) modified |
| 2026-06-06 | NCT07391774 Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed… |
Recruitment opened |
| 2026-06-06 | NCT07391774 Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed… |
Trial sites expanded: 0 -> 14 locations |
| 2026-06-05 | NCT07174336 A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in… |
Trial sites expanded: 324 -> 327 locations |
| 2026-06-05 | NCT05183828 Effect of HSD3B1 (1245C) Gene Mutation on Treatment of Stage I-III Breast Cancer |
Trial terminated — check why_stopped for reason |
| 2026-06-05 | NCT05183828 Effect of HSD3B1 (1245C) Gene Mutation on Treatment of Stage I-III Breast Cancer |
critical why stopped: null → "Study ended earlier than anticipated due to end of funding." |
| 2026-06-05 | NCT05183828 Effect of HSD3B1 (1245C) Gene Mutation on Treatment of Stage I-III Breast Cancer |
date change Primary completion moved earlier: 2026-06-30 -> 2026-05-13 |
| 2026-06-05 | NCT05183828 Effect of HSD3B1 (1245C) Gene Mutation on Treatment of Stage I-III Breast Cancer |
date change Completion moved earlier: 2026-06-30 -> 2026-05-13 |
| 2026-06-04 | NCT07492641 BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or… |
Trial sites expanded: 4 -> 13 locations |
| 2026-06-03 | NCT05827081 Phase IIIb Study of Ribociclib + ET in Early Breast Cancer |
Trial sites expanded: 207 -> 215 locations |
| 2026-05-29 | NCT04568616 Phase II Study of Neoadjuvant ArOMatase Inhibitor Therapy for ER+ Breast Cancer (NAOMI) |
date change Primary completion pushed: 2025-04-02 -> 2028-04-02 |
| 2026-05-28 | NCT06492616 A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2… |
Trial sites expanded: 536 -> 541 locations |
| 2026-05-28 | NCT07604571 Study of IEV407 as Single Agent or in Combination in Patients With Advanced HR+/HER2… |
Recruitment opened |
| 2026-05-23 | NCT07492641 BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or… |
Recruitment opened |
| 2026-05-23 | NCT07492641 BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or… |
Trial sites expanded: 0 -> 4 locations |
| 2026-05-21 | NCT06143631 Prescription of Letrozole for Uterine Myoma |
date change Primary completion pushed: 2027-06-30 -> 2027-09-06 |
| 2026-05-21 | NCT06143631 Prescription of Letrozole for Uterine Myoma |
date change Completion pushed: 2027-06-30 -> 2027-12-13 |
| First Posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-06-03 | NCT07624903 Letrozole Versus Methotrexate for Management of Undisturbed Ectopic Pregnancy | Phase 2 | Not Yet Recruiting |
| 2026-06-01 | NCT07616427 Fovinaciclib Plus Aromatase Inhibitors and Dual HER2 Blockade in a Response-Adapted… | Phase 2 | Recruiting |
| 2026-06-01 | NCT07616453 Efficacy and Safety of Culmerciclib Plus Aromatase Inhibitors in a Response-Adapted… | Phase 2 | Recruiting |
| 2026-06-01 | NCT07616973 Letrozole vs. Clomiphene Citrate Plus Tamoxifen for Ovulation Induction and Pregnancy… | Phase 3 | Active, Not Recruiting |
| 2026-06-01 | NCT07618923 Neoadjuvant Dalpiciclib + AI → SHR-A1811 for HR+/HER2-Low Breast Cancer | Phase 2 | Not Yet Recruiting |
| 2026-05-22 | NCT07604272 Reversing InGuinal Hernia Trial: The Evaluation of Sex Hormones to Reverse Inguinal… | Phase 1 | Not Yet Recruiting |
| 2026-05-22 | NCT07604571 Study of IEV407 as Single Agent or in Combination in Patients With Advanced HR+/HER2… | Phase 1 | Recruiting |
| 2026-05-19 | NCT07596212 BRE-06: Study to Increase Tolerance to Aromatase Inhibitors for Patients With Early-Stage… | Phase 1/2 | Not Yet Recruiting |
| 2026-05-15 | NCT07589075 Sodium-Glucose Co-Transporter-2 Inhibitors as Adjuvant Therapy With Letrozole in… | Phase 4 | Completed |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 4 | |||
| NCT06143631 | Prescription of Letrozole for Uterine Myoma | Leiomyoma, Uterine | Recruiting |
| NCT05161195 | Roll-over Study to Allow Continued Access to Ribociclib | Metastatic Breast Cancer | Active, Not Recruiting |
| Phase 3 | |||
| NCT06016738 | OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced… | Breast Cancer | Recruiting |
| NCT06072781 | A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous… | Low Grade Serous Ovarian Cancer | Recruiting |
| NCT07400523 | Ribociclib in Hormone Receptor-positive, HER2-negative Early Breast Cancer With Residual… | Breast Cancer | Recruiting |
| NCT05774951 | A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of… | Breast Cancer, Early Breast Cancer | Recruiting |
| NCT05586802 | Sex Steroids Balance for Metabolic and Reproductive Health in Klinefelter Syndrome | Klinefelter Syndrome | Recruiting |
| NCT05512364 | Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA) | ER-positive Breast Cancer | Recruiting |
| NCT06380751 | Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine… | Advanced Breast Cancer | Recruiting |
| NCT07085767 | Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2… | Breast Cancer | Recruiting |
| NCT06492616 | A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2… | Breast Cancer | Recruiting |
| NCT05952557 | An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early… | Breast Cancer, Early Breast Cancer | Recruiting |
| NCT06790693 | A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and… | Breast Cancer | Recruiting |
| NCT07492641 | BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or… | HR+/HER2- Breast Cancer | Recruiting |
| NCT03011684 | Fertility Preservation Using Tamoxifen and Letrozole in Estrogen Sensitive Tumors Trial | Infertility | Recruiting |
| NCT07174336 | A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in… | Breast Neoplasms | Recruiting |
| NCT05827081 | Phase IIIb Study of Ribociclib + ET in Early Breast Cancer | Early Breast Cancer | Recruiting |
| NCT07391774 | Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed… | Anatomic Stage II Breast Cancer AJCC v8 | Recruiting |
| NCT02246621 | A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in… | Breast Cancer | Active, Not Recruiting |
| NCT02763566 | A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer | Breast Cancer | Active, Not Recruiting |
| NCT01674140 | S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer | Breast Cancer | Active, Not Recruiting |
| NCT05909397 | Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in… | Breast Cancer | Active, Not Recruiting |
| NCT02947685 | Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat… | HER-2 Positive Breast Cancer | Active, Not Recruiting |
| NCT04095364 | Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage… | Low Grade Fallopian Tube Serous Adenocarcinoma | Active, Not Recruiting |
| NCT05514054 | A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early… | Breast Neoplasms | Active, Not Recruiting |